

GeNeuro publishes its 2020 Universal Registration Document

Geneva, Switzerland, May 3, 2021 – 7:30 am CEST GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, including multiple sclerosis, publishes its 2020 Universal Registration Document, in English, which has been filed on April 30, 2021 with the “Autorité des Marchés Financiers (AMF)”.

This document is available to the public free of charge, as provided for in applicable legislation, and may be viewed and downloaded on the Company’s website www.geneuro.com

The 2020 Universal Registration Document includes the annual financial report, the auditors’ reports and information about fees paid to statutory auditors, as well as the resolutions submitted to the Annual Shareholders’ Meeting of May 27, 2021.

About GeNeuro

GeNeuro’s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has rights to 17 patent families protecting its technology.

Contacts :

GeNeuro

Jesús Martin-Garcia

Chairman and CEO
+41 22 552 4800
investors@geneuro.com

NewCap (France)

Louis-Victor Delouvrier /
Mathilde Bohin (investors)

+33 1 44 71 98 52
Arthur Rouillé (media)
+33 1 44 71 00 15
geneuro@newcap.eu

Halsin Partners

Mike Sinclair (media)

+44 20 7318 2955
msinclair@halsin.com

LifeSci Advisors

Chris Maggos (investors)

+41 79 367 6254
chris@lifesciadvisors.com